Dr Nenad Macesic

AMR IMPACT THEME

  • AI Solutions for AMR
  • Transmission & Control of AMR in Healthcare
  • Publics, AMR Prevention & Care

EXPERTISE

  • AI for AMR diagnostics using MALDI-TOF mass spectrometry and genomics
  • Genomic surveillance of AMR transmission in hospitals
  • Clinical translation in infectious diseases and infection prevention

Dr Nenad Macesic is an infectious diseases physician and Senior Research Fellow at Monash University, where he leads the Macesic Lab. He is Deputy Director of the Centre to Impact AMR and co-lead of its AI Solutions for AMR Impact Theme. His research uses bacterial genomics, mass spectrometry and artificial intelligence to detect antimicrobial resistance earlier, track how it spreads and prevent infections. He leads STOP-CPE, a national MRFF-funded program on carbapenemase-producing Enterobacterales. He also founded the AI in Microbiology (AIM) Consortium, which links 10 international centres to build and test AI models for AMR.

Dr Macesic completed his infectious diseases training and a Masters in Biomedical Informatics at Columbia University in New York. He completed his PhD in 2020, receiving the Mollie Holman Medal. At Bayside Health (Alfred Hospital), he is Medical Lead of the Clinical ID Genomics Service and the Infection Prevention Unit, and cares for patients with infections after solid organ and haematopoietic stem cell transplants. He was named a Monash 70th Anniversary Fellow in 2026.

AMR FOCUS

  • AI models that predict resistance and strain type from MALDI-TOF mass spectra, the routine identification method in clinical laboratories
  • Genomic prediction of resistance, including the AMR-GNN graph neural network (Nature Communications, 2026)
  • Tracking plasmids and other mobile genetic elements that carry resistance between bacteria
  • Surveillance of hospital reservoirs such as sinks, drains and wastewater (JPI-AMR-funded RESERVOIR study)

IMPACT

  • Bringing genomic sequencing into routine outbreak investigation and patient care through the Alfred Clinical ID Genomics Service
  • Linking laboratories, hospitals, industry and consumers through STOP-CPE to detect and prevent carbapenemase-producing infections

LEADERSHIP

  • Deputy Director: Centre to Impact AMR
  • Impact Theme Co-Lead (AI solutions for AMR): Centre to Impact AMR
  • CIA, STOP-CPE (MRFF)
  • Founder, AI in Microbiology (AIM) Consortium
  • Medical Lead, Clinical ID Genomics Service, Alfred Health
  • Medical Lead, Infection Prevention Unit, Alfred Health
  • Executive member, Victorian Infection and Immunity Network (VIIN)